Voyager Therapeutics, Inc. — Q1 2023 Form 10-Q
Business context and period. This unaudited quarterly report covers the three months ended March 31, 2023. Voyager is a preclinical biotechnology company developing AAV gene therapies and antibody programs for neurological diseases. Its prioritized wholly owned programs include SOD1 gene therapy for ALS and an anti-tau antibody for Alzheimer’s disease; partnered programs include GBA1 and FXN gene therapies with Neurocrine. Voyager reported no product sales.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Collaboration revenue | $150.5 million | $0.7 million |
| Research and development expense | $18.6 million | $14.3 million |
| General and administrative expense | $9.0 million | $7.7 million |
| Operating income (loss) | $122.9 million | $(21.4) million |
| Net income (loss) | $124.0 million | $(21.3) million |
| Operating cash flow | $123.6 million provided | $34.4 million provided |
Q1 collaboration revenue comprised $79.0 million from Novartis, $69.5 million from the 2023 Neurocrine agreement, and $2.0 million from the 2019 Neurocrine collaboration. The resulting profit reflects collaboration and license revenue, not product sales; it should not be read as evidence of recurring product profitability. Research and development costs rose $4.2 million, mainly from increased personnel and external program spending; lower facility costs partly offset the increase.
At March 31, cash and cash equivalents were $268.3 million and marketable securities were $5.0 million, totaling $273.3 million. Current assets were $302.6 million and current liabilities $19.9 million. Total liabilities were $119.3 million, including operating lease liabilities; the filing reports no conventional borrowings in the presented balance sheet. Cash, cash equivalents, and restricted cash increased $169.4 million during the quarter. Financing cash flow included $31.1 million from Neurocrine’s stock purchase. Cash from operations was substantially affected by collaboration-related income and deferred revenue movements.
Material changes and notable transactions
- Neurocrine’s 2023 collaboration covers a GBA1 program and three rare-disease discovery programs. Voyager received an approximately $136.0 million upfront payment and $39.0 million for 4,395,588 shares issued at $8.88 each. The agreement also provides for substantial potential development and commercial milestones and tiered royalties; these are contingent, not guaranteed revenue.
- Voyager recognized $69.5 million for delivery of the GBA1 development and commercialization license. As of March 31, $74.4 million related to the agreement remained deferred revenue, classified as non-current.
- Novartis exercised options for capsids targeting two undisclosed targets, effective March 1. Voyager recognized $79.0 million of revenue: $54.0 million previously deferred for the exercised options and expiration of a third option, plus a $25.0 million option fee recorded as a receivable at quarter-end. The $25.0 million was received in April. Novartis did not license a third target, and rights for that target reverted to Voyager.
- Common shares outstanding increased to 43.4 million at March 31 from 38.6 million at year-end, principally reflecting the Neurocrine issuance.
Outlook, risks, and other matters
- Management expects existing cash, cash equivalents, and marketable securities at March 31, the $25.0 million Novartis payment received in April, and expected Neurocrine cost reimbursements to fund planned operations and capital expenditures into 2025. This is management’s estimate and depends in part on anticipated collaboration receipts.
- The anti-tau lead candidate, VY-TAU01, was selected in January 2023; Voyager expects an IND filing in the first half of 2024. It reported receiving FDA pre-IND written feedback in April and expects to begin GLP toxicology work later in 2023.
- Voyager delayed its expected SOD1 lead-candidate selection from the first half to the second half of 2023 and currently expects an IND in mid-2025; it plans to update the IND timeline after candidate selection.
- All pipeline programs were in preclinical development. The company expects expenses to rise as development advances and states it will need substantial additional funding over time. Financing may dilute shareholders or require granting rights to programs or technologies.
- Key risks include preclinical and clinical development uncertainty, regulatory delays, manufacturing and collaboration execution, intellectual-property matters, and the possibility that additional financing will not be available on acceptable terms. There were no material pending legal proceedings or litigation reserves reported at March 31. Management assessed disclosure controls as effective at the reasonable-assurance level.
Important facts for investors to verify
- Whether the reported collaboration revenue and Q1 profit are primarily one-time license and option accounting events rather than recurring operating performance.
- Timing and terms of Neurocrine cost reimbursements, future milestones, and any potential royalties; milestone and royalty amounts depend on future events and product sales.
- Whether the estimated cash runway into 2025 remains achievable as research, development, and operating costs increase.
- Progress against the revised SOD1 candidate-selection and IND timelines, and the anti-tau IND-enabling plan and first-half 2024 filing target.
- Share dilution and the precise accounting and economics of the Neurocrine equity issuance and collaboration consideration.